
George Lundberg, MD Editor in Chief at Cancer Commons
-
April 12, 2021
Long-Term Survival Data for Olaparib Maintenance in Ovarian Cancer Show Clinically Meaningful Boost Bookmark
George Lundberg, MDCancer Network reports results from 5 years of follow up for a clinical trial in which the drug olaparib (Lynparza) was given to people who had already been treated for relapsed, high-grade serous, or endometrioid ovarian cancer—including primary peritoneal or fallopian tube cancer. Overall survival data show that olaparib outperformed a placebo drug for these patients, suggesting the possibility that it could be an effective “maintenance therapy.”
.
-
April 12, 2021
FDA Grants Full Approval to Sacituzumab Govitecan for Triple-Negative Breast Cancer Bookmark
George Lundberg, MDRecurrent triple-negative breast cancer is particularly difficult to treat. As reported by Cancer Network, the U.S. Food and Drug Administration (FDA) has now approved the drug sacituzumab govitecan (Trodelvy) for treating people with this disease, depending on their stage and treatment history.
.
-
April 12, 2021
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer Bookmark
George Lundberg, MDAn academic research paper published in The New England Journal of Medicine reports new results from a phase III, randomized, double-blinded, controlled clinical trial. In the trial, people with esophageal or gastroesophageal junction cancer that had been surgically resected were treated with either a placebo drug or the drug nivolumab. All patients had previously received chemotherapy before resection and had residual disease after surgery. The findings suggest that nivolumab may be beneficial, as median disease-free survival in was doubled (22 versus 11 months) in the nivolumab treated group compared to the placebo group.
.
-
April 12, 2021
Lenvatinib/Pembrolizumab Improves Survival in Advanced Endometrial Cancer Bookmark
George Lundberg, MDThe ASCO Post reports on new results from a clinical trial testing a combination of the drugs lenvatinib and pembrolizumab in people with advanced or recurrent endometrial cancer. The results show that, compared to standard chemotherapy, this drug combo improves both overall and progression-free survival—according to both statistical and clinical analysis.
.
-
March 16, 2021
Acute Myeloid Leukemia (AML)—An Overview Bookmark
George Lundberg, MDOverview from Medscape curated by Contributing Editor George Lundberg, MD, who notes:
This 2020 encyclopedic update with treatment options for all stages of acute myeloid leukemia is comprehensive and clear. (Free registration required, written with a physician audience in mind.)
.
-
February 20, 2021
COVID-19 Vaccination: The VOICE for Patients with Cancer Bookmark
George Lundberg, MDThis piece from the scientific journal Nature Medicine describes a new clinical trial studying vaccination against COVID-19 specifically in patients with cancer.
.
-
February 20, 2021
Patients with Cancer Less Likely to Enroll in Clinical Trials Due to COVID-19 Bookmark
George Lundberg, MDFewer patients with cancer may be willing to enter a clinical trial. This Cancer Network article explains why and offers solutions.
.
-
February 20, 2021
NCI-Supported Clinical Trials for Coronavirus Bookmark
George Lundberg, MDThis list from the National Cancer Institute outlines many government-supported clinical trials for COVID-19 that may be specifically for cancer survivors.
.
-
February 20, 2021
What Cancer Survivorship Can Teach Us About COVID-19 Bookmark
George Lundberg, MDCancer survivors and (especially long) COVID-19 survivors may have a lot in common, as outlined in this opinion piece from STAT.
.
-
February 20, 2021
Patient education: Pancreatic cancer (Beyond the Basics) Bookmark
George Lundberg, MDUpToDate provides an authoritative overview of pancreatic cancer diagnosis and treatment.
.